Cross-continental patent coverage = multiple markets with real barriers to entry. Not just defensive — commercial assets that can be licensed, partnered, and monetized.
#YDBio#Patents#IP#PrecisionMedicine
Technology can be learned. Patents are much harder to get around.
YD Bio's IP portfolio has been quietly expanding 🧵
✨Pipeline → https://t.co/1WRtODnBXw
🔹 Cancer detection patents — licensed across the Americas, Europe & Asia-Pacific
🔹 Pancreatic cancer IP — U.S. granted
🔹 Colorectal cancer — key markets advancing
🔹 Ophthalmology platform — exclusive license
🎗️June is #NationalCancerSurvivorsMonth. Survival starts with early detection.
OkaiDx™ uses DNA methylation-based technology to find cancer before it advances. 💙
👉 Order now → https://t.co/TiVYvlM5tY
🌏 Market: Expansion planned for Maryland, Pennsylvania, Rhode Island & New Jersey. Taiwan & Hong Kong launch in progress. Up to 3 acquisitions in evaluation.
👉 Follow us for updates: https://t.co/WQiVSiK9Gr
#YDBio#Biotech #2026
n 2026, there are a few things worth watching at YD Bio.
Three platforms.
Multiple catalysts.
Here's the breakdown 🧵
👉 Full roadmap → https://t.co/1WRtODo9N4
Three tracks running in parallel: research, clinical development, and consumer products. Stem cell therapy is closer than most people think.
Follow us for updates 👁️→ https://t.co/wYczqM7ikG
#YDBio#Exosome#StemCell
"Stem cell therapy = injecting cells into your eye." Not quite. YD Bio uses exosomes — tiny repair-signal packets naturally secreted by limbal stem cells.
Applied as eye drops. No live cell implantation needed 🧵
📍"Still lab-stage?"
No. Full FDA documentation filed. Clinical research launching in Taiwan in 2026.
📍"Regular people can't access it?"
Exovisse™ is already available in the U.S.
Not a grey area. Properly checked. Exovisse™ is now available nationwide across the U.S.
👉 Learn more → https://t.co/N2ef02TmbO
#YDBio#Exovisse#FDA#EyeHealth
When you pick up eye drops or put in contacts, how do you know they're safe?
There's actually a real FDA system behind that. A quick breakdown using YD Bio's Exovisse™ as the example 🧵
🔹 Contact Lenses: FDA 510(k) cleared — reviewed and confirmed safe before going on sale
🔹 Artificial Tears: meet FDA OTC standards, authorized for nationwide sales across the U.S.
👁️ Can the eye actually heal itself?
Dry eye, macular degeneration, corneal damage — conditions affecting hundreds of millions, with no real path to recovery. Until now.
YD Bio is changing that.
🔗 https://t.co/WQiVSiJBQT
In 2025, we delivered:
🔹 Exovisse™ Contact Lenses — FDA 510(k) cleared
🔹 Exovisse™ Artificial Tears — OTC-compliant, now available across the U.S.
🔹 LSC Exosomes — enrolled in the FDA Drug Master File
Next up: LSC exosome therapeutics for dry eye, glaucoma and corneal injury, with exosome-based lenses and artificial tears planned for clinical trials in 2027. 🌿
We'll share more as the work progresses.
👁️ Regenerative science is starting to make its way into everyday eye care.
YD Bio (Nasdaq: $YDES) has entered the U.S. ophthalmology market with partner 3D Global Biotech. 🧬
👉 https://t.co/LgQlmgaqwx
Two products are already cleared:
✅ Exovisse™ Contact Lenses — FDA 510(k) (Class II)
✅ Exovisse™ Artificial Tears — FDA OTC Monograph M018, sold nationwide
Both available now to help with dry eyes. 💧
🌍 Leading institutions worldwide are converging on dendritic cell immunotherapy for GBM.
🇧🇷 São Paulo — Phase III registered
🇳🇴 Oslo — Phase II/III recruiting
🇹🇼 SSMC — Phase III underway in Taiwan
This is why YD Bio is advancing its acquisition of SSMC. 🩶